会員登録
ログイン
【4889】レナサイエンス
医療現場の課題を解決するため医薬品、医療機 器、人工知能(AI)等を活用して新たな医療ソリューションを研究 開発
類似企業：
【業界1位】
協和キリン
【業界1位】
協和キリン
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026.03 | 2025/11/12 | Q2予 | 133 | ↑ | +17.7% | +17.7% | -380 | ↑ | +4.3% | +4.3% | -343 | ↑ | +13.6% | +13.6% | -345 | ↑ | +4.7% | +4.7% |
| 2026.03 | 2025/08/13 | Q1予 | 113 | → | 0.0% | 0.0% | -397 | → | 0.0% | 0.0% | -397 | → | 0.0% | 0.0% | -362 | → | 0.0% | 0.0% |
| 2026.03 | 2025/05/14 | 当初予 | 113 | - | - | - | -397 | - | - | - | -397 | - | - | - | -362 | - | - | - |
| 2025.03 | 2025/05/14 | 実 | 132 | ↑ | +3.9% | +46.7% | -178 | ↑ | +33.3% | +35.3% | -178 | ↑ | +33.3% | +35.3% | 113 | ↑ | +145.7% | +204.6% |
| 2025.03 | 2025/02/13 | Q3予 | 127 | → | 0.0% | +41.1% | -267 | → | 0.0% | +2.9% | -267 | → | 0.0% | +2.9% | 46 | → | 0.0% | +142.6% |
| 2025.03 | 2024/12/06 | 修正予 | 127 | ↑ | +21.0% | +41.1% | -267 | ↓ | -3.9% | +2.9% | -267 | ↓ | -3.9% | +2.9% | 46 | ↑ | +150.5% | +142.6% |
| 2025.03 | 2024/11/14 | Q2予 | 105 | → | 0.0% | +16.7% | -257 | → | 0.0% | +6.5% | -257 | → | 0.0% | +6.5% | -91 | → | 0.0% | +15.7% |
| 2025.03 | 2024/08/08 | Q1予 | 105 | → | 0.0% | +16.7% | -257 | → | 0.0% | +6.5% | -257 | → | 0.0% | +6.5% | -91 | → | 0.0% | +15.7% |
| 2025.03 | 2024/07/03 | 修正予 | 105 | ↑ | +16.7% | +16.7% | -257 | ↑ | +6.5% | +6.5% | -257 | ↑ | +6.5% | +6.5% | -91 | ↑ | +15.7% | +15.7% |
| 2025.03 | 2024/05/09 | 当初予 | 90 | - | - | - | -275 | - | - | - | -275 | - | - | - | -108 | - | - | - |
| 2024.03 | 2024/05/09 | 実 | 194 | ↓ | -21.8% | -21.8% | -252 | ↓ | -3.7% | -3.7% | -251 | ↓ | -3.3% | -3.3% | -258 | ↓ | -5.7% | -5.7% |
| 2024.03 | 2024/02/08 | Q3予 | 248 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -244 | → | 0.0% | 0.0% |
| 2024.03 | 2023/11/09 | Q2予 | 248 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -244 | → | 0.0% | 0.0% |
| 2024.03 | 2023/08/10 | Q1予 | 248 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -243 | → | 0.0% | 0.0% | -244 | → | 0.0% | 0.0% |
| 2024.03 | 2023/05/11 | 当初予 | 248 | - | - | - | -243 | - | - | - | -243 | - | - | - | -244 | - | - | - |
| 2023.03 | 2023/05/11 | 実 | 100 | → | 0.0% | +11.1% | -333 | ↓ | -1.2% | +38.6% | -333 | ↓ | -1.2% | +38.6% | -335 | ↓ | -1.2% | +38.2% |
| 2023.03 | 2023/03/09 | 修正予 | 100 | ↑ | +11.1% | +11.1% | -329 | ↑ | +39.3% | +39.3% | -329 | ↑ | +39.3% | +39.3% | -331 | ↑ | +38.9% | +38.9% |
| 2023.03 | 2023/02/09 | Q3予 | 90 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% |
| 2023.03 | 2022/11/10 | Q2予 | 90 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% |
| 2023.03 | 2022/08/10 | Q1予 | 90 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% | -542 | → | 0.0% | 0.0% |
| 2023.03 | 2022/05/12 | 当初予 | 90 | - | - | - | -542 | - | - | - | -542 | - | - | - | -542 | - | - | - |
| 2022.03 | 2022/05/12 | 実 | 139 | → | 0.0% | +13.9% | -210 | ↑ | +20.2% | +46.8% | -241 | ↑ | +18.0% | +39.6% | -254 | ↑ | +13.6% | +36.5% |
| 2022.03 | 2022/02/14 | Q3予 | 139 | ↑ | +13.9% | +13.9% | -263 | ↑ | +33.4% | +33.4% | -294 | ↑ | +26.3% | +26.3% | -294 | ↑ | +26.5% | +26.5% |
| 2022.03 | 2021/11/11 | 当初予 | 122 | - | - | - | -395 | - | - | - | -399 | - | - | - | -400 | - | - | - |
